SNIBE(SZ:300832) Sou Hu Cai Jing·2025-07-31 10:32Group 1 - The core viewpoint of the articles highlights the performance and market position of Shenzhen New Industry Biomedical Engineering Co., Ltd. in the medical device sector, particularly in the in vitro diagnostics field [1] - As of July 31, the company's stock closed at 55.52 yuan, down 3.24%, with a rolling PE ratio of 23.71 times and a total market capitalization of 43.623 billion yuan [1] - The average PE ratio for the medical device industry is 54.89 times, with a median of 37.06 times, placing the company at the 49th position within the industry [1][2] - The company has 48 institutional holders, all of which are funds, holding a total of 33.4155 million shares valued at 1.895 billion yuan [1] - The company specializes in the research, production, sales, and customer service of in vitro diagnostic products, with its main products being diagnostic instruments and reagents [1] - The company received the "National Brand Gold Award" for medical equipment in 2024 and ranked first in various customer satisfaction metrics in tertiary hospitals, indicating strong customer recognition of its services [1] - In the latest quarterly report for Q1 2025, the company achieved a revenue of 1.125 billion yuan, a year-on-year increase of 10.12%, and a net profit of 438 million yuan, a year-on-year increase of 2.65%, with a gross profit margin of 68.01% [1] Group 2 - The company's PE (TTM) is 23.71, while the static PE is 23.86, and the price-to-book ratio is 4.84 [2] - Comparatively, the industry average PE (TTM) is 54.89, and the median is 37.06, indicating that the company is significantly below the industry average [2] - Other companies in the industry have varying PE ratios, with the lowest being 10.93 for Jiuan Medical and the highest being 19.94 for Antu Biology, showcasing a wide range of valuations within the sector [2]